Cell and Gene Therapy Production and Commercialization Track

The industry is rapidly moving from autologous (patient-specific) cell therapies toward off-the-shelf allogeneic approaches. This shift is vital to improving patient access, reducing cost-of-goods, and enabling wider commercialisation. Find out how engineering strategies for allogeneic CAR-T cells, are increasing scale without compromising quality, supply chain frameworks, and process optimisation. Join sessions such as: “Scaling genome-edited allogeneic CAR-T manufacturing to increase access to cell therapies” which will explore how to bring allogeneic therapies to market efficiently.

For viral vector-based gene therapies (especially AAV), success hinges on robust process development, meeting regulatory expectations, designing for scalability, and bridging to commercial launch. Talks such as: “From Bench to BLA: Critical Attributes of AAV Vector Manufacturing Process Development” will look at modelling supply needs, COGS, clearance, purity, productivity and regulatory readiness.

With the complexity and cost of cell and gene therapies high, the push for manufacturing efficiency, automation, process analytics and digital tools is more urgent than ever. Session such as: “Improving Efficiency of Cell Therapy Manufacturing Through Full Automation” will highlight the trend toward integrated, lean, data-driven production platforms for both autologous and allogeneic formats.

Ensuring product quality, stability, and supply-chain resilience is fundamental as cell and gene therapies move toward scale. Sessions on analytical strategy, formulation, and supply-chain planning for critical materials (e.g., mRNA, vectors) reflect how the industry must tightly control quality attributes, shelf-life, cold chain, and critical raw-material sourcing.